Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-23P (RNA, U2 small nuclear 23, pseudogene) is a human pseudogene of the U2 small nuclear RNA (snRNA) family. Pseudogenes like RNU2-23P do not produce functional RNA and are considered noncoding genomic elements. Unlike functional U2 snRNA genes (such as RNU2-1 or RNU2-2), which are integral to the major spliceosome's role in pre-mRNA splicing, pseudogenes such as RNU2-23P are not expressed or biologically functional. Recent advances have clarified that previously annotated U2 pseudogenes (like RNU2-2P, now recognized as RNU2-2) can sometimes have biological roles; however, there is no evidence that RNU2-23P functions as either a gene product or a therapeutic target[1][2][3]. Key Notes: - The designation “pseudogene” denotes that RNU2-23P does not code for a functional molecule and has no known physiological or pathological relevance[2][3]. - Misidentification is possible in literature because other U2-related snRNA genes (such as RNU2-2, previously labeled as RNU2-2P) have recently been shown to have functional consequences, but this does **not** apply to RNU2-23P[2]. - RNU2-23P is not a drug target, receptor, enzyme, or actionable biomolecule. It is best described as a nonfunctional genomic element. If you are seeking information about a functionally relevant U2 snRNA gene, consider RNU2-1 or RNU2-2—the latter was previously (incorrectly) annotated as a pseudogene ("RNU2-2P") but is now established as a functional gene with disease relevance[2]. RNU2-23P, the specific subject of your query, does not meet criteria for a therapeutic, diagnostic, or functional molecular target.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 23, pseudogene (RNU2-23P).